Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana.

The Open AIDS Journal Pub Date : 2017-06-30 eCollection Date: 2017-01-01 DOI:10.2174/1874613601711010045

M Mosepele, V Letsatsi, L Mokgatlhe, F P Hudson, R Gross

{"title":"Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana.","authors":"M Mosepele, V Letsatsi, L Mokgatlhe, F P Hudson, R Gross","doi":"10.2174/1874613601711010045","DOIUrl":null,"url":null,"abstract":"Background: Little is known about the use of statin for cardiovascular disease (CVD) risk reduction among HIV-infected patients on protease inhibitors (PI`s) in sub-Saharan Africa (SSA).Objective: Cholesterol screening and statin use were retrospectively assessed among HIV-infected participants on PI`s between 2008 and 2012 at a large urban HIV clinic in Botswana.Methods: Proportion of participants screened per year was calculated and statin indication was assessed using atherosclerosis CVD (ASCVD) and Framingham risk (FRS) scores as of the year 2012 guidelines.Results: Cholesterol screening ranged between 19% and 30% per year (2008-2011) but increased to 80% after study enrollment. The rate of hypercholesterolemia (> 5.0 mmol/L) was 31% in 2012. Fewer than 1% participants were on statin therapy but 14.3% and 9.4% had statins indicated by ASCVD and FRS respectively.Conclusion: The high proportion of participants indicated for, but not prescribed statins highlights a substantial gap in the care to reduce CVD risk among these patients.","PeriodicalId":515834,"journal":{"name":"The Open AIDS Journal","volume":"11 ","pages":"45-51"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543697/pdf/","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open AIDS Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874613601711010045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

Abstract

Background: Little is known about the use of statin for cardiovascular disease (CVD) risk reduction among HIV-infected patients on protease inhibitors (PI`s) in sub-Saharan Africa (SSA).

Objective: Cholesterol screening and statin use were retrospectively assessed among HIV-infected participants on PI`s between 2008 and 2012 at a large urban HIV clinic in Botswana.

Methods: Proportion of participants screened per year was calculated and statin indication was assessed using atherosclerosis CVD (ASCVD) and Framingham risk (FRS) scores as of the year 2012 guidelines.

Results: Cholesterol screening ranged between 19% and 30% per year (2008-2011) but increased to 80% after study enrollment. The rate of hypercholesterolemia (> 5.0 mmol/L) was 31% in 2012. Fewer than 1% participants were on statin therapy but 14.3% and 9.4% had statins indicated by ASCVD and FRS respectively.

Conclusion: The high proportion of participants indicated for, but not prescribed statins highlights a substantial gap in the care to reduce CVD risk among these patients.

Abstract Image

查看原文本刊更多论文

在博茨瓦纳接受蛋白酶抑制剂治疗的hiv感染者中，胆固醇筛查和他汀类药物处方较低。

背景:在撒哈拉以南非洲(SSA)使用蛋白酶抑制剂(PI’s)的hiv感染患者中，使用他汀类药物降低心血管疾病(CVD)风险的情况知之甚少。目的:回顾性评估2008年至2012年在博茨瓦纳一家大型城市HIV诊所接受PI检查的HIV感染者的胆固醇筛查和他汀类药物使用情况。方法:计算每年筛查的参与者比例，并根据2012年指南使用动脉粥样硬化CVD (ASCVD)和Framingham风险(FRS)评分评估他汀类药物适应症。结果:每年(2008-2011年)胆固醇筛查率在19% - 30%之间，但在研究入组后增加到80%。2012年高胆固醇血症(> 5.0 mmol/L)发生率为31%。不到1%的参与者接受他汀类药物治疗，但14.3%和9.4%的参与者分别接受ASCVD和FRS适应症的他汀类药物治疗。结论:高比例的参与者表示，但没有开他汀类药物，这表明在降低这些患者心血管疾病风险的护理方面存在巨大差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Open AIDS Journal

自引率

0.00%

发文量